FoxHollow Delays Pursuit Of SilverHawk Coronary Artery Disease Indication
This article was originally published in The Gray Sheet
Executive Summary
FoxHollow has once again delayed the start of a clinical trial to study the treatment of coronary artery disease with the SilverHawk plaque excision system
You may also be interested in...
Device Newcomer And Pharma Giant Expand Partnership
Merck is buying an 11% stake in device maker FoxHollow, expanding a previous agreement to use plaque isolated from patients' arteries for pharmaceutical research
Device Newcomer And Pharma Giant Expand Partnership
Merck is buying an 11% stake in device maker FoxHollow, expanding a previous agreement to use plaque isolated from patients' arteries for pharmaceutical research
FoxHollow Finds Rinspiration For Cardiac Market Entry Via Kerberos Purchase
FoxHollow's acquisition of the Rinspiration thrombectomy device through its $32 mil. purchase of Kerberos Proximal Solutions provides the firm with immediate access to the coronary market